Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KRYS NASDAQ:MTSR NASDAQ:PCVX NYSE:RCUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRYSKrystal Biotech$187.18+2.3%$154.29$122.80▼$207.84$5.30B0.64379,228 shs257,700 shsMTSRMetsera$52.84-0.1%$38.58$12.30▼$54.47$5.56BN/A3.65 million shs1.98 million shsPCVXVaxcyte$40.74-2.7%$33.10$27.66▼$118.62$5.44B1.122.10 million shs1.57 million shsRCUSArcus Biosciences$15.05+7.3%$11.32$6.50▼$18.98$1.49B0.77964,504 shs1.20 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRYSKrystal Biotech+2.27%+4.21%+28.91%+25.00%+7.06%MTSRMetsera-0.11%+1.38%+50.54%+45.12%+5,283,999,900.00%PCVXVaxcyte-2.70%+7.13%+25.70%+12.42%-63.54%RCUSArcus Biosciences+7.38%+11.70%+31.72%+58.34%-13.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRYSKrystal Biotech$187.18+2.3%$154.29$122.80▼$207.84$5.30B0.64379,228 shs257,700 shsMTSRMetsera$52.84-0.1%$38.58$12.30▼$54.47$5.56BN/A3.65 million shs1.98 million shsPCVXVaxcyte$40.74-2.7%$33.10$27.66▼$118.62$5.44B1.122.10 million shs1.57 million shsRCUSArcus Biosciences$15.05+7.3%$11.32$6.50▼$18.98$1.49B0.77964,504 shs1.20 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRYSKrystal Biotech+2.27%+4.21%+28.91%+25.00%+7.06%MTSRMetsera-0.11%+1.38%+50.54%+45.12%+5,283,999,900.00%PCVXVaxcyte-2.70%+7.13%+25.70%+12.42%-63.54%RCUSArcus Biosciences+7.38%+11.70%+31.72%+58.34%-13.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKRYSKrystal Biotech 2.75Moderate Buy$209.0011.66% UpsideMTSRMetsera 2.38Hold$55.755.51% UpsidePCVXVaxcyte 2.75Moderate Buy$106.25160.80% UpsideRCUSArcus Biosciences 2.56Moderate Buy$23.3855.32% UpsideCurrent Analyst Ratings BreakdownLatest RCUS, PCVX, MTSR, and KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025KRYSKrystal BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025MTSRMetseraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025RCUSArcus BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025RCUSArcus BiosciencesTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.00 ➝ $39.009/30/2025MTSRMetseraWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$54.009/27/2025KRYSKrystal BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025MTSRMetseraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025PCVXVaxcyteWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025RCUSArcus BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/24/2025MTSRMetseraLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/24/2025MTSRMetseraLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$77.00 ➝ $57.00(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKRYSKrystal Biotech$290.52M18.65$4.74 per share39.47$32.90 per share5.69MTSRMetseraN/AN/AN/AN/A($2.46) per shareN/APCVXVaxcyteN/AN/AN/AN/A$26.52 per shareN/ARCUSArcus Biosciences$258M6.21N/AN/A$5.30 per share2.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKRYSKrystal Biotech$89.16M$4.9238.0418.57N/A40.85%15.21%13.81%11/3/2025 (Estimated)MTSRMetsera-$209.13MN/A0.00∞N/AN/AN/AN/AN/APCVXVaxcyte-$463.93M-$4.11N/AN/AN/AN/A-16.85%-15.92%11/4/2025 (Estimated)RCUSArcus Biosciences-$283M-$3.17N/AN/AN/A-109.56%-55.96%-25.73%11/5/2025 (Estimated)Latest RCUS, PCVX, MTSR, and KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/5/2025Q3 2025RCUSArcus Biosciences-$1.28N/AN/AN/A$20.25 millionN/A11/4/2025Q3 2025PCVXVaxcyte-$1.23N/AN/AN/AN/AN/A11/3/2025Q3 2025KRYSKrystal Biotech$1.04N/AN/AN/A$93.72 millionN/A8/6/2025Q2 2025PCVXVaxcyte-$1.12-$1.22-$0.10-$1.22N/AN/A8/6/2025Q2 2025RCUSArcus Biosciences-$1.14-$1.1053+$0.0347N/A$32.86 million$160.00 million8/4/2025Q2 2025KRYSKrystal Biotech$1.08$1.29+$0.21$1.29$95.42 million$96.04 million7/28/2025Q2 2025MTSRMetseraN/A-$0.66N/A-$0.66N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKRYSKrystal BiotechN/AN/AN/AN/AN/AMTSRMetseraN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKRYSKrystal BiotechN/A9.689.33MTSRMetseraN/A5.265.26PCVXVaxcyteN/A11.1111.11RCUSArcus Biosciences0.184.504.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKRYSKrystal Biotech86.29%MTSRMetseraN/APCVXVaxcyte96.78%RCUSArcus Biosciences92.89%Insider OwnershipCompanyInsider OwnershipKRYSKrystal Biotech13.70%MTSRMetseraN/APCVXVaxcyte3.10%RCUSArcus Biosciences9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKRYSKrystal Biotech21028.94 million24.98 millionOptionableMTSRMetsera81105.06 millionN/AN/APCVXVaxcyte160129.82 million125.80 millionOptionableRCUSArcus Biosciences500106.43 million96.21 millionOptionableRCUS, PCVX, MTSR, and KRYS HeadlinesRecent News About These CompaniesHIF-2a Inhibitor Casdatifan Shows Promise for Patients with Kidney CancerOctober 8 at 6:35 PM | targetedonc.comTWeiss Ratings Reaffirms "Sell (D-)" Rating for Arcus Biosciences (NYSE:RCUS)October 8 at 12:19 PM | marketbeat.comTruist Securities Reiterates Arcus Biosciences (RCUS) Buy RecommendationOctober 7 at 12:39 AM | msn.comA Fresh Look at Arcus Biosciences (RCUS) Valuation After New Casdatifan Data and Expanded Pipeline InitiativesOctober 7 at 11:53 AM | finance.yahoo.comArcus Biosciences (RCUS) Soars 8.5%: Is Further Upside Left in the Stock?October 7 at 10:41 AM | zacks.comArcus Biosciences, Inc. (RCUS) Shareholder/Analyst Call TranscriptOctober 6 at 12:01 AM | seekingalpha.comArcus Biosciences (NYSE:RCUS) Trading Up 15.2% - Here's What HappenedOctober 6 at 6:21 PM | marketbeat.comArcus Biosciences, Inc. (RCUS) Shareholder/Analyst Call - SlideshowOctober 6 at 1:34 PM | seekingalpha.comArcus Biosciences announces new data for casdatifanOctober 6 at 1:19 PM | msn.comArcus Biosciences stock soars after promising kidney cancer drug dataOctober 6 at 1:19 PM | investing.comArcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor EventOctober 6 at 8:00 AM | businesswire.comArcus Biosciences, Inc. (NYSE:RCUS) Receives $21.14 Consensus Price Target from BrokeragesOctober 4, 2025 | americanbankingnews.comArcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of "Moderate Buy" from AnalystsOctober 1, 2025 | marketbeat.comArcus Biosciences (NYSE:RCUS) CAO Alexander Azoy Sells 2,831 SharesSeptember 30, 2025 | marketbeat.comArcus Biosciences Announces New Employment Inducement GrantsSeptember 24, 2025 | businesswire.comArcus Biosciences, Inc. $RCUS Shares Purchased by Rhumbline AdvisersSeptember 20, 2025 | marketbeat.comArcus Biosciences, Inc. $RCUS Shares Purchased by Goldman Sachs Group Inc.September 16, 2025 | marketbeat.comArcus Biosciences, Inc. $RCUS Shares Acquired by Woodline Partners LPSeptember 12, 2025 | marketbeat.comArcus Biosciences (NYSE:RCUS) Stock Price Down 8% - Here's WhySeptember 10, 2025 | marketbeat.comArcus Biosciences, Inc. (RCUS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comJacobs Levy Equity Management Inc. Acquires 506,853 Shares of Arcus Biosciences, Inc. $RCUSSeptember 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRCUS, PCVX, MTSR, and KRYS Company DescriptionsKrystal Biotech NASDAQ:KRYS$187.18 +4.16 (+2.27%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$187.23 +0.05 (+0.03%) As of 10/8/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Metsera NASDAQ:MTSR$52.84 -0.06 (-0.11%) As of 10/8/2025 04:00 PM EasternMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.Vaxcyte NASDAQ:PCVX$40.74 -1.13 (-2.70%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$41.84 +1.10 (+2.70%) As of 10/8/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Arcus Biosciences NYSE:RCUS$15.05 +1.02 (+7.27%) Closing price 10/8/2025 03:59 PM EasternExtended Trading$15.35 +0.30 (+1.99%) As of 10/8/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal AMD and OpenAI: A Partnership That Just Redrew the AI Map EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End Falcon Flex Drives Growth as CrowdStrike Bets on AI Security Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
